Journal of Schizophrenia Disorders And Therapy

Aims and Scope

Journal of Schizophrenia Disorders And Therapy (JSDT) is an open access, peer-reviewed journal dedicated to advancing research, understanding, and treatment of schizophrenia and related disorders. JSDT serves as a vital resource for researchers, healthcare professionals, and patients, providing access to the latest scientific discoveries and therapeutic developments in the field.  
 

Scope and Focus:

The journal fosters an interdisciplinary approach, covering diverse topics including but not limited to:  

• Neurobiology and Neuroimaging: Advances in brain structure and function studies related to schizophrenia.  
• Pharmacology, Genetics, and Neurochemistry: Genetic markers, neurotransmitter systems, and pharmacological interventions.  
• Neurodevelopmental Aspects: Early-life risk factors and developmental influences on schizophrenia.  
• Clinical Descriptions and Treatment: Diagnosis, symptomatology, and novel therapeutic approaches.  
• Behavioral Therapies: Cognitive-behavioral interventions and psychosocial rehabilitation techniques.  
• Impact on Quality of Life: Social, occupational, and emotional challenges faced by individuals with schizophrenia.  
• Epidemiology and Public Health Impact: Prevalence, risk factors, and socio-economic burden of schizophrenia.  
• Comorbidities in Schizophrenia: Co-occurring psychiatric and medical conditions.  
• Cultural Aspects of Schizophrenia: Cultural influences on perception, treatment, and stigma.  
• Integrated Treatment Approaches: Multimodal treatment strategies including medication, therapy, and community support.  
• Mental Health Services and Policy: Accessibility, effectiveness, and innovations in schizophrenia care systems.  

JSDT explores the intersection of AI and schizophrenia, such as the use of artificial intelligence (AI) in diagnosis, treatment, or understanding the underlying mechanisms of the disorder. Contributions from the following research areas are invited but not limited to the following branches:

• Adolescent-onset schizophrenia
• Attention-deficit/hyperactivity disorder
• Autism spectrum disorder
• Bipolar disorder
• Clozapine
• Cognitive impairment
• Cognitive Science
• Cognitive-behavioral therapy
• Complementary and alternative medicine
• Deep brain stimulation
• Delusions
• Depression
• Dual diagnosis
• Electroconvulsive therapy
• Family therapy
• First-episode psychosis
• First-generation antipsychotics
• Group therapy
• Hallucinations
• Herbal remedies
• Hyperprolactinemia
• Integrated care
• Long-term prognosis
• Major depressive disorder
• Medication management
• Mental Health Illiteracy
• Mental Health Morbidity
• Negative symptoms
• Animal-assisted therapy
• Neurodevelopmental disorders
• Neuropsychology
• Obsessive-compulsive disorder
• Antipsychotic medications
• Occupational therapy
• Paranoid type
• Personality disorders
• Pharmacogenomics
• Positive symptoms
• Post-traumatic stress disorder
• Prolactin
• Psychopharmacology
• Psychosis
• Anxiety disorders
• Psychotherapy
• Psychotic disorders
• Recovery-oriented services
• Schizoaffective Disorder
• Second-generation antipsychotics
• Social skills training
• Substance use disorders
• Suicide tendency
• Supportive psychotherapy
• Telepsychiatry
• Transcranial magnetic stimulation
• Virtual reality therapy
• Vocational training